Concepedia

David Vensel

DV

Statistics

Publications

4

Citations

271

H-Index

4

Active since

2003

Affiliations

Arqule (United States)(Current)

David Vensel is an author at Arqule (United States) specializing in drug discovery, pharmacy, and potency optimization.

Publications per year

2003–2016

4

Publications

4

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 111 citations · Full text

, , +17

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 100 citations · Full text

, , +17

The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands

Manish Tandon, Mary‐Margaret O'Donnell, Alex Porte et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 31 citations · Full text

, , +12

Calix[4]arene, calix[4]resorcarene, and cyclodextrin derivatives and their lanthanide complexes as chiral NMR shift reagents

Kristin J. Smith, James D. Wilcox, Gudrun Mirick et al. · Chirality · 2003 · 29 citations · Full text

, , +10

1–4 of 4